2013-12-08 01:00:38 - Recently published research from GlobalData, "EpiCast Report: Hemophilia - Epidemiology Forecast to 2022", is now available at Fast Market Research
Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues and within mucous membranes, which can be spontaneous or could be due to internal or external trauma, depending on the severity of the disease. The clinical presentation of hemophilia ranges from mild to moderate to severe stages depending on the residual level of the circulating factor (Rocino et al., 2012; Srivastava et al., 2012; White et al., 2001).
Full Report Details at
- www.fastmr.com/prod/724861_epicast_report_hemophilia_epidemiolog ..
Hemophilia is a rare disease
but the prevalence of hemophilia varies according to the economic status of a country. The exact cause for the variation in prevalence between countries based on their economic status is unknown. However, researchers attribute the lower prevalence in lower-income countries to insufficient reporting of these data due to the lack of access to healthcare and impaired diagnostic capabilities because of little or no treatment due to lower economic funds in low-income countries (Evatt, 2005; Skinner, 2006; Stonebraker et al., 2010).
In 2012, the 9MM had 56,762 diagnosed prevalent cases of hemophilia A and B, 30% of which occurred in the US. The diagnosed prevalent cases of hemophilia in the 9MM are expected to increase slightly to 58,072 cases by 2022 (Figure 1). Throughout the forecast for the 9MM, the US will have the largest proportion of diagnosed prevalent cases of hemophilia A and B, with 30.90% of all the diagnosed prevalent cases of hemophilia A and B in the 9MM. Because hemophilia is an inherited condition, it requires lifelong treatment. Given the increase in prevalence of cardiovascular diseases with advancing age and increasing life expectancy in hemophiliacs due to advances in treatment, the challenges faced by hemophiliacs may increase in the near future, as well as the need for supporting treatments and care.
* The Hemophilia EpiCast Report provides an overview of the risk factors and epidemiological trends for hemophilia in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Argentina, and China). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of both hemophilia A and B segmented by age, (ages 0 to greater or equal to 85 years), and sex in these markets.
* The Hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
* The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
Reasons to Get this Report
* Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
* Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
* Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
Partial Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.2.1 Almost 50% of Hemophilia Patients are Affected by Hypertension
3.3 Global Trends
3.4 Epidemiological Forecast of Hemophilia (2012-2022)
3.4.1 Forecast Methodology
3.4.2 Sources Used
3.4.3 Sources Not Used
3.4.4 Forecast Assumptions and Methods
3.5 Epidemiology Forecast (2012-2022), Hemophilia A
3.5.1 Diagnosed Prevalent Cases of Hemophilia A
3.5.2 Diagnosed Prevalent Cases of Hemophilia A by Age
3.5.3 Diagnosed Prevalent Cases of Hemophilia A by Sex
3.5.4 Age-Standardized Prevalence of Diagnosed Hemophilia A
3.6 Epidemiology Forecast (2012-2022), Hemophilia B
3.6.1 Diagnosed Prevalent Cases of Hemophilia B
3.6.2 Diagnosed Prevalent Cases of Hemophilia B by Age
3.6.3 Diagnosed Prevalent Cases of Hemophilia B by Sex
3.6.4 Age-Standardized Prevalence of Diagnosed Hemophilia B
3.7 Epidemiology Forecast (2012-2022), Hemophilia A and B
3.7.1 Diagnosed Prevalent Cases of Hemophilia A and B
3.7.2 Diagnosed Prevalent Cases of Hemophilia A and B by Sex
3.8.1 Conclusions on Epidemiological Trends
3.8.2 Limitations of the Analysis
3.8.3 Strengths of the Analysis
4.2 About the Authors
4.2.3 Global Director of Epidemiology and Health Policy
4.2.4 Global Head of Healthcare
4.3 About GlobalData
4.4 About EpiCast
List of Tables
1.1 List of Tables
Table 1: Relationship of Bleeding Severity with Clotting Factor Level
Table 2: 9MM, Prevalence of Hemophilia A in Men (per 100,000 Population), All Ages, 1998-2006
Table 3: 9MM, Prevalence of Hemophilia B in Men (per 100,000 Population), All Ages, 1998-2006
Table 4: 9MM, Sources of Hemophilia A and Hemophilia B Prevalence Data
Table 5: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2012-2022
Table 6: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, Row (%), 2012
Table 7: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, Row (%), 2012
Full Table of Contents is available at:
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.